Expectations trend
FY2027 · fiscal year ending 2027-12-31 · fmp
Vera Therapeutics, Inc. (VERA)
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
$30.14-5.72%
Close 2026-11-05 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.
Next-FY EPS estimate change · 30 days
Matching fiscal periods, usable estimates and at least one analyst are required.
One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.
The calculation requires same-period, same-provider snapshots, positive EPS, at least one analyst and a baseline within three days of the requested lookback.
The EPS and P/E reference is not available for VERA yet.
| Measure / period | Management expectations | Analyst expectations |
|---|
Management figures unavailable.
Current consensus figures unavailable.
Three published thesis conditions, with dated milestones shown separately.
| Key Factor | Why It Matters | Current Status | Break Condition | Latest Evidence |
|---|---|---|---|---|
Control of operating losses and cash burn | The company is focused on controlling its operating losses and cash burn despite current challenges. | Under Pressure | Net losses and cash burn exceed $100M per quarter persistently beyond FY26 | Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management context |
Compare these dated observations with the operating requirements above
FY2027 · fiscal year ending 2027-12-31 · fmp
The evidence, the remaining questions, and what comes next
No recovery evidence is reported in the available driver assessments.
Nov 5, 2026
Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.
Observed price history; separate from operating scenarios
The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.
This is a clinical-stage biotechnology company moving into commercial launch, so the thesis depends on both regulatory progress and adoption. The thesis is in a watch state: key milestones are progressing, but recent financial performance remains weak and confidence in the overall read is low.
The evidence gives no valuation level or clear account of market expectations, so it is not possible to judge whether VERA is cheap, fair, or expensive versus peers. The muted share-price response to recent developments suggests the news has not prompted a strong reaction, but does not establish what expectations are priced in.
Near term, the company remains loss-making, and its recent financial performance is weak despite a reported earnings beat. Atacicept has accelerated approval and its U.S. launch is underway; early TRUTAKNA launch uptake and the successful ORIGIN 3 final analysis are constructive execution signs, while the supplemental filing and later full-approval milestones remain ahead.
Over the next year, the thesis hinges on launch uptake, progress toward the supplemental filing, and the pivotal two-year data expected in early 2027. A guidance cut or further weakening in jobs data could add pressure, while stronger results and guidance from sector bellwethers could support the Healthcare backdrop.
For the 1-3 year view, VERA has meaningful regulatory and launch progress, but the evidence still points to a loss-making, higher-risk business with weak recent performance. The thesis depends on commercial execution and follow-through on the remaining clinical and regulatory milestones. Not investment advice.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Stated in 2 of 2 supplied quarters. Management reported: “During the six months ended June 30, 2026, net cash used in operating activities was $206.8 million, compared to $109.2 million for the quarter ended June 30, 2025.” “Vera Therapeutics reported $596.8 million in cash, cash equivalents, and marketable securities as of March 31, 2026, which combined with availability under its debt facility, Vera Therapeutics believes to be sufficient to fund operations through potential approval and U.S. commercial launch of atacicept and beyond.”
FDA approval progress for Atacicept in IgA Nephropathy | Vera Therapeutics is advancing its key drug Atacicept toward full FDA approval, which could unlock significant value. | Improving | FDA delays or denies full approval beyond next 4 quarters | Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Revenue growth from clinical program progress | A supporting condition in Vera Therapeutics, Inc.'s published investment case. The stated target is Revenue grows toward $253.5M by FY27. | Intact | Revenue fails to grow beyond $38M in FY26 and declines thereafter | Revenue: $0 FY2026-Q2; GAAP. Published target: Revenue grows toward $253.5M by FY27. Annual target cannot be compared with a quarterly or TTM observation. Aug 10, 20260 USD · source valueLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.
$-3.91 → $-4.27 · observed estimates
$0.26B → $0.23B · observed estimates
One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.
| Snapshot | EPS | Revenue | EPS / revenue analysts |
|---|---|---|---|
| 2026-07-24 | $-3.91 | $261,096,287 | 8 / 8 |
| 2026-07-25 | $-3.86 | $261,074,200 | 8 / 11 |
| 2026-07-26 | $-3.86 | $261,074,200 | 8 / 11 |
| 2026-07-27 | $-3.86 | $261,074,200 | 8 / 11 |
| 2026-07-28 | $-3.86 | $261,074,200 | 8 / 11 |
| 2026-07-29 | $-3.91 | $261,096,287 | 8 / 8 |
| 2026-07-30 | $-3.86 | $261,074,200 | 8 / 11 |
| 2026-07-31 | $-3.91 | $261,096,287 | 8 / 8 |
| 2026-08-01 | $-3.91 | $261,096,287 | 8 / 8 |
| 2026-08-02 | $-3.91 | $261,096,287 | 8 / 8 |
| 2026-08-03 | $-3.91 | $261,096,287 | 8 / 8 |
| 2026-08-04 | $-3.86 | $261,074,200 | 8 / 11 |
| 2026-08-05 | $-3.86 | $261,074,200 | 8 / 11 |
| 2026-08-06 | $-3.86 | $261,074,200 | 8 / 11 |
| 2026-08-08 | $-3.86 | $261,074,200 | 8 / 11 |
| 2026-08-09 | $-3.86 | $261,074,200 | 8 / 11 |
| 2026-08-10 | $-3.91 | $261,100,104 | 8 / 8 |
| 2026-08-12 | $-3.91 | $261,100,104 | 8 / 8 |
| 2026-08-13 | $-3.91 | $261,100,104 | 8 / 8 |
| 2026-08-14 | $-3.91 | $261,100,104 | 8 / 8 |
| 2026-08-15 | $-3.91 | $261,100,104 | 8 / 8 |
| 2026-08-16 | $-3.91 | $261,100,104 | 8 / 8 |
| 2026-08-17 | $-3.91 | $261,100,104 | 8 / 8 |
| 2026-08-18 | $-3.91 | $261,100,104 | 8 / 8 |
| 2026-08-19 | $-3.91 | $261,100,104 | 8 / 8 |
| 2026-08-20 | $-4.28 | $234,896,368 | 8 / 8 |
| 2026-08-21 | $-4.28 | $234,896,368 | 8 / 8 |
| 2026-08-22 | $-4.28 | $234,896,368 | 8 / 8 |
| 2026-08-23 | $-4.28 | $234,896,368 | 8 / 8 |
| 2026-08-24 | $-4.28 | $234,896,368 | 8 / 8 |
| 2026-08-25 | $-4.28 | $234,896,368 | 8 / 8 |
| 2026-08-26 | $-4.28 | $234,896,368 | 8 / 8 |
| 2026-08-27 | $-4.28 | $234,896,368 | 8 / 8 |
| 2026-08-28 | $-4.28 | $234,896,368 | 8 / 8 |
| 2026-08-29 | $-4.28 | $234,896,368 | 8 / 8 |
| 2026-08-30 | $-4.28 | $234,896,368 | 8 / 8 |
| 2026-08-31 | $-4.28 | $234,896,368 | 8 / 8 |
| 2026-09-01 | $-4.45 | $220,205,459 | 8 / 8 |
| 2026-09-02 | $-4.45 | $220,205,459 | 8 / 8 |
| 2026-09-03 | $-4.45 | $220,209,277 | 8 / 8 |
| 2026-09-04 | $-4.45 | $220,209,277 | 8 / 8 |
| 2026-09-05 | $-4.45 | $220,209,277 | 8 / 8 |
| 2026-09-06 | $-4.45 | $220,209,277 | 8 / 8 |
| 2026-09-07 | $-4.45 | $220,209,277 | 8 / 8 |
| 2026-09-08 | $-4.43 | $221,239,238 | 8 / 8 |
| 2026-09-09 | $-4.43 | $221,212,944 | 8 / 8 |
| 2026-09-10 | $-4.43 | $221,212,944 | 8 / 8 |
| 2026-09-11 | $-4.43 | $221,212,944 | 8 / 8 |
| 2026-09-12 | $-4.43 | $221,212,944 | 8 / 8 |
| 2026-09-13 | $-4.43 | $221,212,944 | 8 / 8 |
| 2026-09-14 | $-4.43 | $221,212,944 | 9 / 8 |
| 2026-09-15 | $-4.43 | $221,212,944 | 9 / 8 |
| 2026-09-16 | $-4.43 | $221,212,944 | 9 / 8 |
| 2026-09-17 | $-4.43 | $221,212,944 | 9 / 8 |
| 2026-09-18 | $-4.43 | $221,212,944 | 9 / 8 |
| 2026-09-19 | $-4.43 | $221,212,944 | 9 / 8 |
| 2026-09-20 | $-4.43 | $221,212,944 | 9 / 8 |
| 2026-09-21 | $-4.43 | $221,212,944 | 9 / 8 |
| 2026-09-22 | $-4.43 | $221,212,944 | 9 / 8 |
| 2026-09-23 | $-4.43 | $221,212,944 | 9 / 8 |
| 2026-09-24 | $-4.43 | $221,212,944 | 9 / 8 |
| 2026-09-25 | $-4.43 | $221,212,944 | 9 / 8 |
| 2026-09-26 | $-4.43 | $221,212,944 | 9 / 8 |
| 2026-09-27 | $-4.43 | $221,212,944 | 9 / 8 |
| 2026-09-28 | $-4.43 | $221,212,944 | 9 / 8 |
| 2026-09-29 | $-4.43 | $221,212,944 | 9 / 8 |
| 2026-09-30 | $-4.43 | $221,212,944 | 9 / 8 |
| 2026-10-01 | $-4.43 | $221,212,944 | 9 / 8 |
| 2026-10-02 | $-4.43 | $221,212,944 | 9 / 8 |
| 2026-10-03 | $-4.35 | $221,212,944 | 9 / 8 |
| 2026-10-04 | $-4.35 | $221,212,944 | 9 / 8 |
| 2026-10-05 | $-4.35 | $221,212,944 | 9 / 8 |
| 2026-10-06 | $-4.35 | $221,212,944 | 9 / 8 |
| 2026-10-07 | $-4.35 | $221,212,944 | 9 / 8 |
| 2026-10-08 | $-4.35 | $221,212,944 | 9 / 8 |
| 2026-10-09 | $-4.26 | $230,700,035 | 9 / 8 |
| 2026-10-10 | $-4.26 | $230,700,035 | 9 / 8 |
| 2026-10-11 | $-4.27 | $228,704,834 | 9 / 8 |
| 2026-10-12 | $-4.27 | $228,704,834 | 9 / 8 |
| 2026-10-13 | $-4.25 | $232,371,097 | 9 / 9 |
| 2026-10-14 | $-4.25 | $232,371,097 | 9 / 9 |
| 2026-10-15 | $-4.25 | $232,371,097 | 9 / 9 |
| 2026-10-16 | $-4.25 | $232,371,097 | 9 / 9 |
| 2026-10-17 | $-4.25 | $232,371,097 | 9 / 9 |
| 2026-10-18 | $-4.25 | $232,371,097 | 9 / 9 |
| 2026-10-19 | $-4.25 | $232,371,097 | 9 / 9 |
| 2026-10-20 | $-4.25 | $233,769,664 | 9 / 9 |
| 2026-10-21 | $-4.25 | $233,769,664 | 9 / 9 |
| 2026-10-22 | $-4.25 | $233,769,664 | 9 / 9 |
| 2026-10-23 | $-4.25 | $233,768,114 | 9 / 9 |
| 2026-10-24 | $-4.25 | $233,768,114 | 9 / 9 |
| 2026-10-25 | $-4.25 | $233,768,114 | 9 / 9 |
| 2026-10-26 | $-4.25 | $233,768,114 | 9 / 9 |
| 2026-10-27 | $-4.25 | $233,768,114 | 9 / 9 |
| 2026-10-28 | $-4.25 | $233,768,114 | 9 / 9 |
| 2026-10-29 | $-4.25 | $233,768,114 | 9 / 9 |
| 2026-10-30 | $-4.25 | $233,768,114 | 9 / 9 |
| 2026-10-31 | $-4.27 | $230,333,306 | 9 / 9 |
| 2026-11-01 | $-4.27 | $230,333,306 | 9 / 9 |
| 2026-11-02 | $-4.27 | $230,333,306 | 9 / 9 |
| 2026-11-03 | $-4.27 | $230,333,306 | 9 / 9 |
| 2026-11-04 | $-4.27 | $230,333,306 | 9 / 9 |
Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.
Latest: 13 Buy / Strong Buy · 2 Hold · 0 Sell / Strong Sell
Recent actions · Oct 6–Nov 4 · 0 recorded
0 raises · 0 cuts · 0 unchanged · 1 without a comparable prior
Oct 6, 2026–Nov 4, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.
3 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.
The dated weekly assessment and its assumptions are available in Read detailed Outlook.